Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries

Hospital Clinic, University of Barcelona, Spain. betriu001@msn.com

OBJECTIVES: We sought to assess the incidence and clinical relevance of examination data to recurrent ischemia within an international randomized trial. BACKGROUND: Ischemic symptoms commonly recur after thrombolysis for acute myocardial infarction. METHODS: Patients (n = 40,848) were prospectively evaluated for recurrent angina and transient electrocardiographic (ECG) or hemodynamic changes. Five groups were developed: Group 1, patients with no signs or symptoms of recurrent ischemia; Group 2, patients with angina only; Group 3, patients with angina and ST segment changes; Group 4, patients with angina and hemodynamic abnormalities; and Group 5, patients with angina, ST segment changes and hemodynamic abnormalities. Baseline clinical and outcome variables were compared among the five groups. RESULTS: Group 1 comprised 32,717 patients, and Groups 2 to 5 comprised 20% of patients (4,488 in Group 2; 3,021 in Group 3; 337 in Group 4; and 285 in Group 5). Patients with recurrent ischemia were more often female, had more cardiovascular risk factors and less often received intravenous heparin. Significantly more extensive and more severe coronary disease, antianginal treatment, angioplasty and coronary bypass surgery were observed as a function of ischemic severity. The 30-day reinfarction rate was 1.6% in Group 1, 6.5% in Group 2, 21.7% in Group 3, 13.1% in Group 4 and 36.5% in Group 5 (p < 0.0001); in contrast, the 30-day mortality rate was significantly lower (p < 0.0001) in Groups 1, 2 and 3 (6.6%, 5.4% and 7.7%, respectively) than in Groups 4 and 5 (21.8% and 29.1%). CONCLUSIONS: Postinfarction angina greatly increases the risk of reinfarction, especially when accompanied by transient ECG changes. However, mortality is markedly increased only in the presence of concomitant hemodynamic abnormalities.

This article has been cited by other articles:

				M. R. Le May, G. A. Wells, M. Labinaz, R. F. Davies, M. Turek, D. Leddy, J. Maloney, T. McKibbin, B. Quinn, R. S. Beanlands, et al. Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI Study) J. Am. Coll. Cardiol., August 2, 2005; 46(3): 417 - 424. [Abstract] [Full Text] [PDF]

				A. Rodriguez-Sinovas, J. Bis, I. Anivarro, J. de la Torre, A. Bayes-Genis, and J. Cinca Coronary smooth muscle reactivity to muscarinic stimulation after ischemia-reperfusion in porcine myocardial infarction J Appl Physiol, July 1, 2003; 95(1): 81 - 88. [Abstract] [Full Text] [PDF]

				M. C. Tjandrawidjaja, Y. Fu, S. G. Goodman, F. Van de Werf, C. B. Granger, P. W. Armstrong, and for the ASSENT-2 Investigators The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2{star} Eur. Heart J., June 1, 2003; 24(11): 1024 - 1034. [Abstract] [Full Text] [PDF]

				E. Ronner, R.T. van Domburg, M.J.B.M. van den Brand, P.J. de Feyter, D.P. Foley, W.J. van der Giessen, P.W. Serruys, and M.L. Simoons Platelet GP IIb/IIIa receptor blockers for failed thrombolysis in acute myocardial infarction, alone or as adjunct to other rescue therapies. A single centre retrospective analysis of 548 consecutive patients with acute myocardial infarction Eur. Heart J., October 1, 2002; 23(19): 1529 - 1537. [Abstract] [Full Text] [PDF]

				M. M. Pelter, M. G. Adams, and B. J. Drew Association of Transient Myocardial Ischemia With Adverse In-Hospital Outcomes for Angina Patients Treated in a Telemetry Unit or a Coronary Care Unit Am. J. Crit. Care., July 1, 2002; 11(4): 318 - 325. [Abstract] [Full Text] [PDF]

				M. P. Hudson, C. B. Granger, E. J. Topol, K. S. Pieper, P. W. Armstrong, G. I. Barbash, A. D. Guerci, A. Vahanian, R. M. Califf, and E. M. Ohman Early Reinfarction After Fibrinolysis: Experience From the Global Utilization of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO III) Trials Circulation, September 11, 2001; 104(11): 1229 - 1235. [Abstract] [Full Text] [PDF]

				P. W. Armstrong, Y. Fu, W.-C. Chang, E. J. Topol, C. B. Granger, A. Betriu, F. Van de Werf, K. L. Lee, R. M. Califf, and f. t. G.-I. Investigators Acute Coronary Syndromes in the GUSTO-IIb Trial : Prognostic Insights and Impact of Recurrent Ischemia Circulation, November 3, 1998; 98(18): 1860 - 1868. [Abstract] [Full Text] [PDF]

				Clinical Correlates of Postinfarction Ischemia Journal Watch Cardiology, January 26, 1998; 1998(126): 5 - 5. [Full Text]